Who to call at Processa Pharmaceuticals, Inc., and when
Fundz watches for the moments Processa Pharmaceuticals, Inc. starts buying, and tells you who to reach.
- An alert the day Processa Pharmaceuticals, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Processa Pharmaceuticals, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Processa Pharmaceuticals, Inc.. With Fundz connected, it knows.
Processa Pharmaceuticals, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
processapharmaceuticals.comExecutive Summary
Analysis of 8-K filing content
Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer effective November 4, 2026, with a $700,000 annual salary, discretionary bonus up to 60%, and equity grant of 3.0% of fully-diluted shares. This leadership addition brings pharmaceutical industry experience from his prior CEO role at Ambros Therapeutics.
Quick answer
Processa Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 4, 2026 under Item 5.02 (Executive Change). Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer effective November 4, 2026, with a $700,000 annual salary, discretionary bonus up to 60%, and equity grant of 3.0% of fully-diluted shares.
- What did Processa Pharmaceuticals, Inc. disclose in its 8-K filed November 4, 2026?
- Processa Pharmaceuticals appointed Gregory J. Flesher as Chief Operating Officer effective November 4, 2026, with a $700,000 annual salary, discretionary bonus up to 60%, and equity grant of 3.0% of fully-diluted shares. This leadership addition brings pharmaceutical industry experience from his prior CEO role at Ambros Therapeutics.
- What does 8-K Item 5.02 (Executive Change) mean?
- A senior executive or director joined, left, or changed roles. Companies generally must file it within four business days of the event.
- Which other companies filed an 8-K Item 5.02 around the same time?
- Noble Corporation plc (November 4, 2026), Thunder Mountain Gold, Inc. (November 4, 2026), Penguin Solutions, Inc. (November 4, 2026) and Siebert Financial Corp. (November 4, 2026) also filed an Item 5.02 8-K within a week of Processa Pharmaceuticals, Inc.
- Where can I read the original Processa Pharmaceuticals, Inc. filing?
- The original filing is on SEC EDGAR (CIK 0001533743), accession number 0001140361-26-041901.
Source: Fundz verified event record.
Other companies that filed an 8-K Item 5.02 (Executive Change) the same week
Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.
- Noble Corporation plc (November 4, 2026): Noble Corporation promoted Joey M. Kawaja from Senior Vice President of Operations to Executive Vice President and Chief Operating Officer effective November 1, 2026, signaling a...
- Thunder Mountain Gold, Inc. (November 4, 2026): Thunder Mountain Gold appointed Dr. Steven A. Osterberg as Senior Vice-President of Exploration effective September 8, 2026, while accepting the resignation of Chief Operating...
- Penguin Solutions, Inc. (November 4, 2026): Penguin Solutions agreed to sell its Cree LED/Optimized LED business to Transom Crystal AcquireCo, LLC in an all-cash transaction expected to close in Q1 2027.
- Siebert Financial Corp. (November 4, 2026): Siebert Financial Corp. appointed Richard S. Gebbia and David J. Gebbia as Co-Chief Executive Officers effective November 4, 2026, with John J. Gebbia transitioning to Chairman.
- Childrens Place, Inc. (November 4, 2026): Multiple executive departures at Children's Place, Inc. occurred in early November 2026, including the resignation of President and Interim CEO Muhammad Asif Seemab and Chief...
- Electronic Servitor Publication Network, Inc. (November 4, 2026): Thomas Spruce resigned on October 29, 2026, from his positions as Director, COO, CFO, and Secretary of Electronic Servitor Publication Network, Inc. Peter Hager, the current...
Key Takeaways
Gregory J. Flesher appointed as COO effective November 4, 2026, bringing prior CEO experience from Ambros Therapeutics
Compensation package includes $700,000 base salary plus discretionary target bonus up to 60% for fiscal 2027
2 more takeaways
Filing Overview
What This Means
Processa Pharmaceuticals, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.